AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal ligation
Number of subjects: 267400
Study 14962728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever having had an induced abortion
Number of subjects: 267400
Study 11281052 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (rhG-CSF) 5 micrograms/kg/day subcutaneous as a supplement to antibiotherapy
Number of subjects: 28
Study 11281052 — intervention group
Group type: COMPARATOR
Intervention: Antibiotherapy alone
Number of subjects: 28
Study 9141211 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-gun administration of hepatitis B vaccine (Engerix‐B)
Number of subjects: 97
Study 9141211 — intervention group
Group type: COMPARATOR
Intervention: Syringe and needle administration of hepatitis B vaccine (Engerix‐B)
Number of subjects: 97
Study 7583725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (Dramamine)
Number of subjects: 300
Study 7583725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 2204773 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 27
Study 2204773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 428220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1521
Study 428220 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 1521
Study 428220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 1521
Study 31573919 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-Mentor app with biofeedback
Number of subjects: 40
Study 31573919 — intervention group
Group type: COMPARATOR
Intervention: Visual instruction without biofeedback
Number of subjects: 40
Study 28249622 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish versions of the DISABKIDS chronic-generic and diabetes-specific modules
Number of subjects: 99
Study 28729319 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated enhanced Recovery following Minimally Invasive colorectal cancer surgery (RecoverMI)
Number of subjects: 0
Study 28729319 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleRecovery (early coordinated outpatient remote televideo conferencing technology)
Number of subjects: 0
Study 24089540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 8192
Study 24089540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 8192
Study 24089540 — intervention group
Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 8192
Study 24089540 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea monotherapy
Number of subjects: 8192
Study 24089540 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus sulfonylurea
Number of subjects: 8192
Study 24089540 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus insulin
Number of subjects: 8192
Study 21854644 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 40
Study 21854644 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 40
Study 21854644 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 40
Study 19548439 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) combined with transcatheter arterial chemoembolization (TACE)
Number of subjects: 67
Study 19548439 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 67
Study 19548439 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM combined with TACE
Number of subjects: 67
Study 17911369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 17911369 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day
Number of subjects: 0
Study 15488216 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study 11517852 — intervention group
Group type: EXPERIMENTAL
Intervention: Placentrex treatment (Inj Placentrex 2 ml by deep intramuscular injection 5 days a week for 15 injections)
Number of subjects: 120
Study 11517852 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (disprin gargles and betamethasone oral drops)
Number of subjects: 120
Study 11517852 — intervention group
Group type: EXPERIMENTAL
Intervention: Placentrex treatment
Number of subjects: 120
Study 11517852 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 120
Study 8674803 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) for 2 weeks
Number of subjects: 48
Study 1499063 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1F Multipurpose catheter
Number of subjects: 50
Study 1499063 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1F catheters (overall)
Number of subjects: 50
Study 1499063 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1F Pigtail catheter
Number of subjects: 50
Study 1499063 — intervention group
Group type: COMPARATOR
Intervention: 6F Judkins catheters
Number of subjects: 50
Study 1499063 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger F sizes (5F and 6F)
Number of subjects: 50
Study 6524612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin-inhibitor naproxen
Number of subjects: 0
Study 6524612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 31303147 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 725
Study 31303147 — intervention group
Group type: COMPARATOR
Intervention: Control (darunavir/cobicistat + emtricitabine/tenofovir disoproxil fumarate)
Number of subjects: 725
Study 31303147 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 725
Study 31303147 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 725
Study 30240941 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrase HIV RNA single-copy assay (iSCA)
Number of subjects: 151
Study 30240941 — intervention group
Group type: COMPARATOR
Intervention: Cobas-TaqMan HIV-1 Assay v2.0
Number of subjects: 151
Study 26756114 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-month duration)
Number of subjects: 206
Study 26756114 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly health newsletter)
Number of subjects: 206
Study 24635904 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported food intake during overt phases
Number of subjects: 59
Study 24635904 — intervention group
Group type: COMPARATOR
Intervention: Actual food intake measured covertly
Number of subjects: 59
Study 24635904 — intervention group
Group type: COMPARATOR
Intervention: Total misreporting (combined observation and reporting effects)
Number of subjects: 59
Study 21847570 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker propranolol
Number of subjects: 0
Study 19172143 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (1.5 mg/kg)
Number of subjects: 28
Study 19172143 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine (1 mg/kg)
Number of subjects: 28
Study 17714128 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician advice, availability of a wall mirror, availability of a partner
Number of subjects: 2126
Study 15848577 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA, PSL, ALG, AZA (Group A)
Number of subjects: 176
Study 15848577 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA, PSL, ALG, DSG (Group B)
Number of subjects: 176
Study 15848577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac, PSL, ALG, DSG (Group C)
Number of subjects: 176
Study 12199319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000, 50,000, and 75,000 IU daily for one year)
Number of subjects: 113
Study 12199319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 9539596 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg of isoproterenol
Number of subjects: 80
Study 9539596 — intervention group
Group type: COMPARATOR
Intervention: 12.5 microg of epinephrine
Number of subjects: 80
Study 7597378 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (alpha-LNA)
Number of subjects: 22
Study 7597378 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid preparation (placebo)
Number of subjects: 22
Study 1978947 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms budesonide daily
Number of subjects: 103
Study 1978947 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide daily
Number of subjects: 103
Study 1978947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 7033865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior vitrectomy during CPKP
Number of subjects: 132
Study 7033865 — intervention group
Group type: COMPARATOR
Intervention: No vitrectomy during CPKP
Number of subjects: 132
Study 7033865 — intervention group
Group type: EXPERIMENTAL
Intervention: APKP with anterior vitrectomy
Number of subjects: 132
Study 7033865 — intervention group
Group type: COMPARATOR
Intervention: CPKP without vitrectomy
Number of subjects: 132
Study 30898339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1280
Study 30898339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1280
Study 28847152 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 30
Study 28847152 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 30
Study 24577065 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated, tailored and multidisciplinary effort (CTM)
Number of subjects: 1386
Study 24577065 — intervention group
Group type: COMPARATOR
Intervention: Ordinary sickness absence management (OSM)
Number of subjects: 1386
Study 23890317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (2 weeks)
Number of subjects: 77
Study 23890317 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 77
Study 23890317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 77
Study 21131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced correction alert
Number of subjects: 59
Study 21131606 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-correction alert
Number of subjects: 59
Study 21131606 — intervention group
Group type: COMPARATOR
Intervention: No alerts (Control)
Number of subjects: 59
Study 19298336 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMC group (rabeprazole 10 mg, amoxicillin 750 mg, metronidazole 250 mg, clarithromycin 200 mg)
Number of subjects: 104
Study 19298336 — intervention group
Group type: COMPARATOR
Intervention: RAM group (rabeprazole 10 mg, amoxicillin 750 mg, metronidazole 250 mg)
Number of subjects: 104
Study 17520441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-dissolving lyophilized tablet (LT)
Number of subjects: 6
Study 17520441 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablet (IR)
Number of subjects: 6
Study 14998848 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum NTx levels
Number of subjects: 250
Study 11915777 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day fasting with daily training activities
Number of subjects: 8
Study 11915777 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day fasting with enhanced physical activity
Number of subjects: 8
Study 11915777 — intervention group
Group type: COMPARATOR
Intervention: Control (no fasting)
Number of subjects: 8
Study 9776150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid
Number of subjects: 200
Study 9776150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7908501 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 97
Study 7908501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 3300409 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine
Number of subjects: 143
Study 3300409 — intervention group
Group type: COMPARATOR
Intervention: Diazepam combined with droperidol
Number of subjects: 143
Study 3300409 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine combined with droperidol
Number of subjects: 143
Study 3300409 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 143
Study 31647139 — intervention group
Group type: EXPERIMENTAL
Intervention: HPFM-b (high protein-fat meal using carbohydrate and fat-protein counting)
Number of subjects: 30
Study 31647139 — intervention group
Group type: COMPARATOR
Intervention: SM (standard meal using carbohydrate counting)
Number of subjects: 30
Study 31647139 — intervention group
Group type: EXPERIMENTAL
Intervention: HPM (high protein meal using carbohydrate counting)
Number of subjects: 30
Study 31647139 — intervention group
Group type: EXPERIMENTAL
Intervention: HPFM-a (high protein-fat meal using carbohydrate counting)
Number of subjects: 30
Study 29232314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-Maltodextrin (FRU + MAL)
Number of subjects: 8
Study 29232314 — intervention group
Group type: COMPARATOR
Intervention: Glucose-Maltodextrin (GLU + MAL)
Number of subjects: 8
Study 28738799 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin shampoo
Number of subjects: 300
Study 28738799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 300
Study 26654631 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong injection (DHI)
Number of subjects: 864
Study 22819912 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN‐α2a (180 mcg/week) plus ribavirin (1000‐1200 mg/day) and amantadine (200mg/day) for 48 weeks
Number of subjects: 43
Study 22819912 — intervention group
Group type: COMPARATOR
Intervention: amantadine (200mg/day) daily for at least 24 weeks (mean 96 weeks)
Number of subjects: 43
Study 20584129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once daily
Number of subjects: 160
Study 17377767 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration (n=8)
Number of subjects: 16
Study 17377767 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=8)
Number of subjects: 16
Study 16301500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 487
Study 16301500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 12145556 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-antioxidant supplementation (allopurinol, vitamins E and C, mannitol, N-acetylcysteine)
Number of subjects: 42
Study 12145556 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study 9468207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (5 mg daily to 10 mg twice daily for 28 days)
Number of subjects: 329
Study 9468207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (5 mg twice daily to 15 mg once daily for 28 days)
Number of subjects: 329
Study 9468207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibrafiban (various doses)
Number of subjects: 329
Study 9468207 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (for 28 days)
Number of subjects: 329
Study 7892866 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal steroids
Number of subjects: 505
Study 7892866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section delivery with antenatal steroids
Number of subjects: 505
Study 7892866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section delivery without antenatal steroids
Number of subjects: 505
Study 7892866 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery without antenatal steroids
Number of subjects: 505
Study 2650470 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium iohexol
Number of subjects: 100
Study 2650470 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast medium diatrizoic acid
Number of subjects: 100
Study 885711 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole cream
Number of subjects: 84
Study 885711 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 84
Study 30403966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet slow‐pull‐back technique (group A)
Number of subjects: 50
Study 30403966 — intervention group
Group type: COMPARATOR
Intervention: Conventional negative suction after stylet removal (group B)
Number of subjects: 50
Study 30403966 — intervention group
Group type: COMPARATOR
Intervention: Non‐suction after stylet removal (group C)
Number of subjects: 50
Study 30403966 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques (group A, B, C)
Number of subjects: 50
Study 29120912 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour system-thinking program and a 2-hour simulation program
Number of subjects: 67
Study 29120912 — intervention group
Group type: COMPARATOR
Intervention: 4-hour case study and a 2-hour simulation program
Number of subjects: 67
Study 27560676 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Er, Cr:YSGG laser
Number of subjects: 30
Study 27560676 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study 25043514 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+EPA (4 g/day)
Number of subjects: 103
Study 25043514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 25043514 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA enrichment
Number of subjects: 103
Study 22317851 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration of lidocaine plus 40 mg methylprednisolone acetate
Number of subjects: 58
Study 22317851 — intervention group
Group type: COMPARATOR
Intervention: Xylocaine plus distilled water (placebo)
Number of subjects: 58
Study 19875309 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ramipril until the morning of surgery (Group B)
Number of subjects: 47
Study 19875309 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ramipril until the morning of surgery and vasopressin infusion (Group C)
Number of subjects: 47
Study 19875309 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of ramipril 24 hours before surgery (Group A)
Number of subjects: 47
Study 17828093 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel Metrogil Denta and toothpaste Mexidol Dent aktiv
Number of subjects: 0
Study 15642550 — intervention group
Group type: COMPARATOR
Intervention: gemfibrozil (1,200 mg/day)
Number of subjects: 39
Study 15642550 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (40 mg/day)
Number of subjects: 39
Study 11792873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study 11792873 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressants
Number of subjects: 0
Study 11792873 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 10649916 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 bonding system applied without prior acid-etching (Group 1)
Number of subjects: 30
Study 10649916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed sensitive roots acid-etched with 35% phosphoric acid for 15 seconds prior to bonding (Group 2)
Number of subjects: 30
Study 7600776 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo preserved with 15 ppm a.i. CMI/MI
Number of subjects: 27
Study 7600776 — intervention group
Group type: COMPARATOR
Intervention: Shampoo preserved with 0.3% imidazolidinyl urea (IU)
Number of subjects: 27
Study 2228058 — intervention group
Group type: EXPERIMENTAL
Intervention: Centperazine (300 mg/day)
Number of subjects: 0
Study 2228058 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC
Number of subjects: 0
Study 2228058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2228058 — intervention group
Group type: EXPERIMENTAL
Intervention: Centperazine
Number of subjects: 0
Study 375449 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine and kanamycin treatment
Number of subjects: 54
Study 375449 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 54
Study 31205182 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (Op)
Number of subjects: 95
Study 31205182 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (NonOp)
Number of subjects: 95
Study 31205182 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio (ICER) for Op compared to NonOp
Number of subjects: 95
Study 28133931 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg intravenously on days 1, 15, 29, and week 8)
Number of subjects: 34
Study 28133931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28133931 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 34
Study 28133931 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept and Placebo
Number of subjects: 34
Study 25623785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam
Number of subjects: 1023
Study 25623785 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular midazolam
Number of subjects: 1023
Study 25623785 — intervention group
Group type: EXPERIMENTAL
Intervention: ETI (any)
Number of subjects: 1023
Study 25623785 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ETI
Number of subjects: 1023
Study 23711438 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl
Number of subjects: 60
Study 23711438 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 20646915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital treatment
Number of subjects: 765
Study 20646915 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 765
Study 19283791 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year exercise program
Number of subjects: 51
Study 19283791 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 51
Study 17616536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate (FCA) 0.1 mg/d
Number of subjects: 21
Study 17616536 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 21
Study 15775731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed transdermal 17beta‐estradiol for 3 months
Number of subjects: 99